Lundbeck Raises 2026 Revenue and Adjusted EBITDA Growth Guidance
Lundbeck now expects 2026 revenue growth of 11% to 12% at constant exchange rates, up from 7% to 9%. Adjusted EBITDA growth is forecast at 15% to 19%, versus 8% to 14% previously. R&D investments are expected to reach approximately DKK 5.6–5.7 billion.
Lundbeck has raised its full-year 2026 financial guidance, citing the continued strong performance of Vyepti® in the U.S. and better-than-expected results from its Partner Markets. The company now expects revenue to grow by 11% to 12% at constant exchange rates (CER), up from its previous forecast of 7% to 9%. Adjusted EBITDA growth is now projected to be 15% to 19% CER, an increase from the prior range of 8% to 14%.
Additionally, the company expects R&D investments to reach approximately DKK 5.6 - 5.7 billion. This update follows strong performance in the first nine months of 2026, where total revenue grew by 13% CER.